FDA panel backs accelerated approval of bedaquiline

FDA's Anti-Infective Drugs Advisory Committee voted 18-0 that efficacy data for Sirturo bedaquiline from Johnson & Johnson (NYSE:JNJ) supported accelerated approval to treat multi-drug-resistant tuberculosis. The panel voted 11-7 that J&J

Read the full 311 word article

How to gain access

Continue reading with a
two-week free trial.